» Articles » PMID: 24142504

Progression of Carcinogen-induced Fibrosarcomas is Associated with the Accumulation of Naïve CD4+ T Cells Via Blood Vessels and Lymphatics

Overview
Journal Int J Cancer
Specialty Oncology
Date 2013 Oct 22
PMID 24142504
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor microenvironment comprises newly formed blood and lymphatic vessels which shape the influx, retention and departure of lymphocytes within the tumor mass. Thus, by influencing the intratumoral composition of lymphocytes, these vessels affect the manner in which the adaptive immune system responds to the tumor, either promoting or impairing effective antitumor immunity. In our study, we utilized a mouse model of carcinogen-induced fibrosarcoma to examine the composition of tumor-infiltrating lymphocytes during tumor progression. In particular, we sought to determine whether CD4(+) Foxp3(+) regulatory T cells (Tregs) became enriched during tumor progression thereby contributing to tumor-driven immunosuppression. This was not the case as the proportion of Tregs and effector CD4(+) T cells actually declined within the tumor owing to the unexpected accumulation of naïve T cells. However, we found no evidence for antigen-driven migration of these T cells or for their participation in an antitumor immune response. Our data support the notion that lymphocytes can enter tumors via aberrantly formed blood and lymphatic vessels. Such findings suggest that targeting both the tumor vasculature and lymphatics will alter the balance of lymphocyte subpopulations that enter the tumor mass. A consideration of this aspect of tumor immunology may be critical to the success of solid cancer immunotherapies.

Citing Articles

Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.

Yu Y, Zhang H, Ren T, Huang Y, Liang X, Wang W J Cell Mol Med. 2020; 24(19):11230-11242.

PMID: 32820615 PMC: 7576232. DOI: 10.1111/jcmm.15687.


Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction.

Colbeck E, Jones E, Hindley J, Smart K, Schulz R, Browne M Cancer Immunol Res. 2017; 5(11):1005-1015.

PMID: 28947544 PMC: 5668144. DOI: 10.1158/2326-6066.CIR-17-0131.


Blocking the recruitment of naive CD4 T cells reverses immunosuppression in breast cancer.

Su S, Liao J, Liu J, Huang D, He C, Chen F Cell Res. 2017; 27(4):461-482.

PMID: 28290464 PMC: 5385617. DOI: 10.1038/cr.2017.34.


Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy.

Thomas S, Rohner N, Edwards E Annu Rev Biomed Eng. 2016; 18:207-33.

PMID: 26928210 PMC: 5518935. DOI: 10.1146/annurev-bioeng-101515-014413.


A distinct chemokine axis does not account for enrichment of Foxp3(+)  CD4(+) T cells in carcinogen-induced fibrosarcomas.

Ondondo B, Colbeck E, Jones E, Smart K, Lauder S, Hindley J Immunology. 2014; 145(1):94-104.

PMID: 25495686 PMC: 4405327. DOI: 10.1111/imm.12430.

References
1.
Schrama D, Thor Straten P, Fischer W, McLellan A, Brocker E, Reisfeld R . Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001; 14(2):111-21. DOI: 10.1016/s1074-7613(01)00094-2. View

2.
Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

3.
Hindley J, Jones E, Smart K, Bridgeman H, Lauder S, Ondondo B . T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 2012; 72(21):5473-82. PMC: 3491872. DOI: 10.1158/0008-5472.CAN-12-1912. View

4.
Westermann J, Ehlers E, Exton M, Kaiser M, Bode U . Migration of naive, effector and memory T cells: implications for the regulation of immune responses. Immunol Rev. 2002; 184:20-37. DOI: 10.1034/j.1600-065x.2001.1840103.x. View

5.
Banerji S, Ni J, Wang S, Clasper S, Su J, Tammi R . LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999; 144(4):789-801. PMC: 2132933. DOI: 10.1083/jcb.144.4.789. View